New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 inhibitors
Real-world evidence study of more than 400,000 patients with type-2 diabetes, 74% of whom did not have a history of established cardiovascular disease, supports the association of CV benefits with use of Farxiga Latest analysis includes heart attack and stroke endpoints, longer follow-up period and six additional countries across Asia Pacific, the Middle East and North America
